Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Capricor Therapeutics ( (CAPR) ).
On December 5, 2025, Capricor Therapeutics announced the pricing of a public offering of 6,000,000 shares of common stock at $25.00 per share, expected to generate gross proceeds of $150 million. The proceeds will support the development and manufacturing of product candidates, working capital, and general corporate purposes, with the offering anticipated to close on December 8, 2025, subject to customary conditions.
The most recent analyst rating on (CAPR) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Capricor Therapeutics stock, see the CAPR Stock Forecast page.
Spark’s Take on CAPR Stock
According to Spark, TipRanks’ AI Analyst, CAPR is a Neutral.
Capricor Therapeutics’ stock score reflects a mix of strong technical momentum and significant financial challenges. The company’s clinical advancements and potential future milestones offer promise, but current financial instability and regulatory hurdles pose risks.
To see Spark’s full report on CAPR stock, click here.
More about Capricor Therapeutics
Capricor Therapeutics is a biotechnology company focused on developing transformative cell and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel, is in late-stage clinical development for treating Duchenne muscular dystrophy (DMD), and the company is also advancing its proprietary StealthX™ platform for targeted delivery of therapeutics.
Average Trading Volume: 2,601,269
Technical Sentiment Signal: Buy
Current Market Cap: $1.16B
See more data about CAPR stock on TipRanks’ Stock Analysis page.